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What is the effect of adjusting epirubicin doses for body
surface area?
NA Dobbs* and CJ Twelves
ICRF Clinical Oncology Unit. Guy's Hospital. London Bridge. London
Summary Doses of cytotoxic drugs are routinely adjusted according to body surface area. We have evaluated this practice in 32 women with
advanced breast cancer treated with single-agent epirubicin 12.5-120 mg m-2. Epirubicin and its metabolites were measured by high-
perforance liquid chromatography (HPLC). Unadjusted plasma clearance was calculated from dose in mg, and adjusted clearance from dose
in mg m-2. Unadjusted clearance did not correlate with surface area, height, weight, per cent ideal body weight orbody mass index. There was
no difference in the coefficient of variation (CV) of adjusted and unadjusted clearance (39.4% and 37.7% respectively). The AUC that would
have resulted from giving an unadjusted dose was calculated. This predicted AUC was accurate, unbiased and had the same CV as the
actual AUC. Similarly, in 11 patients an analysis of actual and predicted neutropenia confirmed that unadjusted dosing would have had no
significant effect on the pattern of myelosuppression. Normalization of epirubicin dosage according to surface area appears not to reduce
either pharmacokinetic or pharmacodynamic variability.
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Many cytotoxic agents have a narrow therapeutic index and doses
are routinely adjusted for surface area in adult patients. There
remains. nevertheless. widespread variability in both clinical and
pharmacokinetic outcome for patients treated with chemotherapy.
The sources of this variability are unclear and cast doubt on the
usefulness of normalization for surface area as a means of
optimizing treatment for individual patients.
In clinical practice. surface area adjustment is the single most
widely used method of modifying dosage. Grochow et al (1990)
evaluated dose modifications for a range ofexperimental and stan-
dard cytotoxics by correlating pharmacokinetic parameters with
height. weight and surface area. Drug clearance correlated with
only one measure (height) for a single cytotoxic. taxol. Reilly and
Workman (1994) stated that '... normalisation ofthe dosage ofanti-
neoplastic drugs using either body weight or predicted surface area
is actually ofvery limited value in producing consistent drug expo-
sure'. Subsequently. a relationship was shown between clearance of
both taxotere (Bruno et al. 1995) and oemcitabine (Allerheiligen et
al. 1994) and surface area However. for most cytotoxics the use of
surface area modification has not been evaluated.
The anthracyclines are among the most widely used cytotoxic
agents. Liver dysfunction (Twelves et al. 1992). gender (Wade et
al. 1992: Dobbs et al. 1995a). obesity (Twelves et al. 1994) and
age (Robert and Hoerni. 1983) have all been reported as influ-
encing anthracycline pharmacokinetics. For over 20 years anthra-
cycline doses have been modified in patients with abnormal liver
tests - although the current recommended dose modifications may
not be optimal (Twelves et al. 1992: Dobbs et al. 1995b) - and
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according to surface area. This paper addresses the foliowing
questions in relation to epirubicin dose modifications: (1) do phys-
ical characteristics influence the arinability in epirubicin pharma-
cokinetics: (2) does adjustment of dose according to surface area
appear to reduce this variability: (3) what would be the effect on
epirubicin pharmacokinetics and pharmacodynamics of aban-
doning surface area dose normalization?
MATERIALS AND METHODS
Patients and teatment
The study was approved by the local ethics committee and all
patients gave written informed consent. Epirubicin pharmaco-
kinetics were studied in 32 women with advanced breast cancer
who had received no prior anthracycline treatment. Pharmaco-
kinetics were studied during their first cycle of chemotherapy. All
patients had normal liverbiochemistry with serum aspartate amino-
transferase (AST) and serum bilirubin levels within the normal
reference range for the hospital laboratory. Normal serum alkaline
phosphatase (ALP) levels were not required as many patients had
radiological evidence ofbone metastases. Creatinine clearance was
estimated using the formula of Lott and Hayton ( 1980).
Patients were treated with epirubicin 12.5-120 me m-3 iven as a
slow bolus intravenous injection. Treatment dose was selected by the
clinician. To reduce the possible bias ofthe older and less fit women
being treated at lower doses. some of the younger patients were
treated using divided doses. In these women the 'studv' dose of
epirubicin was given on day 1 and the remainder administered
48 h later. after completing pharmacokinetic sampling. These
patients were excluded from the pharmacodynamic analysis of
myelosuppression. The following physical measurements Aere
recorded: height. total body weight and surface area Ideal body
weight([BW) was calculated using the formula: IBW = 110 lb + 5 lb
*Present address: ICRF ClinicalOncolog-s Unit Churchill Ho.spital. OldRoad.
Headinrton. Oxford.
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for each inch above/below 5 ft and percentage ideal body weight
(%IBW) determined. Body mass index (BMI) was also calculated.
Treatment continued on a 3-weekly schedule.
Pharmacokinetics and pharmacodynamics
A total of 12 blood samples were taken from an indwelling venous
cannula over the 48 h following treatment. Each sample was taken
into a lithium heparin tube and stored at -20° C pending assay.
Plasma levels of epirubicin and its metabolites were measured by
high-performance liquid chromatography (HPLC) as previously
described (Dobbs and Twelves. 1991). 'Pharmkit' (Johnson and
Woollard. 1983) A-as used to calculate pharmacokinetic parame-
ters. including area under the concentration-time curve (AUC)
corrected for infusion time. which varied from 1.2 to 19 min.
Plasma epirubicin clearance was calculated as dose/AUC.
Unadjusted clearance was calculated from total dose administered
in mg: clearance adjusted for surface area was calculated from
dose in mg M-n. As epirubicin metabolites have little clinical
activity. we report only pharmacokinetics ofthe parent compound.
Haematological toxicity following the first cycle of treatment
was classified according to WHO criteria (WHO. 1979). A nadir
blood count. defined as one between day 10 and day 12 after treat-
ment. was not taken from all patients. Nadir counts were expressed
as both absolute values and per cent change from pretreatment
values (surviving fraction).
Statistics
Variability in pharmacokinetic and pharmacodynamic end points
was expressed as the coefficient of variation (CV%). Univariate
analyses were used to investigate the relationship between phys-
ical or physiological characteristics and epirubicin pharmaco-
kinetics or pharmacodynamics. In this data set correlation
coefficients (r) as low as 0.3 are statistically significant. although
they represent only a weak relationship. We defined values of
r > 0.5 with P < 0.05 as significant in the context ofthis study. The
relative importance of each individual parameter was evaluated
using multivariate analysis. Mean percentage error (MPE) and
mean absolute percentage error (MAPE) were calculated to assess
the accuracy and precision respectively when comparing actual
and predicted AUC and neutrophil nadirs.
RESULTS
The clinical and biochemical characteristics of all 32 patients are
shown in Tables 1 and 2 respectively. All had normal liver serum
transaminases and bilirubin.
In all patients the epirubicin concentration-time data fitted a
triexponential model. There was wide variability in both unad-
justed epirubicin clearance (mean 49.5 1 h- . range 17.7-91.7) and
adjusted clearance (mean 30.5 1 h-1 m-2. range 11.1-58.0). There
was. however. a linear relationship between total epirubicin dose
and AUC (r = 0.80. P < 0.001).
Sources of variability in epirubicin clearance
The influence on variability in unadjusted clearance of epirubicin
of the following factors was investigated: physical characteristics
(surface area, height. total body weight. IBW%) and age.
Table 1 Clinical characterinscs of all patients
Characteristic Mean Median Range
Clinical
Age (years) 55.3 55.5 35-75
ECOG score 1.1 1.0 0-3
No. of disease sites 2.2 3.0 1-5
Treatmrent
Dose (mg rM2) 74.5 75.0 12.5-120
Dose (mg) 122.6 130.0 20-228
Time of treatment (hmin) 11.01 10.50 08:57-14:27
Length of infusion (h) 0.08 0.075 0.02-0.32
Physical
Height (m) 1.56 1.55 1.42-1.73
TBW (kg) 63.4 62.5 43-83
%IBW 111.4 111 78-159
Surface area (in2) 1.63 1.65 1.38-1.86
Table 2 Biochemical and haematological characteristics of all patients
(n= 32)
Characteristic Mean Median Range
Biochemical (normal)
AST (< 43 u A') 24.1 23.0 8-37
Bilirubin (< 23 uLmol et) 6.3 6.0 0-13
ALP (< 255 u 1)-' 229 197.0 61-538
Aibumirm (30-46 g A') 39.6 40.0 31-50
Creatininea (50-130 grmol -1) 83.3 81.5 62-142
Creatinine clearance 70.1 71.4 28.4-118
Haeratlogical (normal)
Haemaglobin$ (12-15 g dt') 11.7 11.6 9.6-15.9
WBC (4-11 x 109 -t)b 7.4 7.0 4.1-14.5
Neutrophisc (2-8 x 109 I-) 5.6 5.5 2.1-12.6
PlateletsP (150 400 x 109 A') 269 259 147-421
an= 31. n= 27. cn= 26.
If adjustment for surface area is important. unadjusted epiru-
bicin clearance should be positively correlated with surface area.
Figure 1 shows that there was also no significant relationship
between unadjusted epirubicin clearance and surface area (r =
-0.12). Similarly, if surface area is a significant factor in deter-
mining epirubicin clearance, the variability in adjusted clearance
should be less than that of total clearance. Over the dose range
12.5-120 mg, m-2 there was no difference in the variation of the
adjusted and unadjusted epirubicin clearance (CV = 39.4%c and
37.7% respectively: P > 0.05). These data show that. whereas
there is substantial variability in epirubicin clearance, this is not
reduced by adjusting for surface area.
There was also no relationship between unadjusted epirubicin
clearance and height (r = -0.01 . body weight (r = -0.15.) IBW%7
(r = -0.17). BMI (r = -0.16) or age (r=-0.12).
Impact of surface area dose adjustment on
pharmacokinetics (AUC)
These findings suggest there is no pharmacokinetic basis for modi-
fying epirubicin dose according to surface area. It may. therefore.
be possible to administer epirubicin at standard doses, without
adjustment for surface area. This was explored further by
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Table 3 Observed and predicted AuC at dose levels 75, 90 and 120 mg mr-2
Dose group BSA (m2) Actual dose Observed AUC Predicted AUC
(mgi) (ng mJ-1 h) (ng miI h)
120 mg r-2 (n= 7)
Mean 1.66 201 3658 3616
s.d. 0.19 22.1 921 618
C.V.% 11.4 10.9 25.2 17.1
90 mg mn2 (n = 8)
Mean 1.65 149 3529 3562
s.d. 0.13 15.5 838 855
CV% 7.8 10.4 23.7 24.0
75 mg n-2 (n= 7)
Mean 1.65 121.5 2056 2040
s.d. 0.13 12.8 877 777
CV% 7.8 10.5 42.6 38.1
Table 4 Cotnpanson of observed and predicted AUC and nadir neutrophil count (n =11)
Dose Observed Predicto Observed Predied Wiference
(Ingr AUC AUC M r nadir (%)
120 2489 2779 1.07 0.96 -0.11 (12)
120 4590 4046 0.40 0.45 0.05 (12)
120 4363 4298 0.11 0.11 0 (0)
120 4478 4286 0.53 0.55 0.02 (4)
75 1785 1728 1.70 1.75 0.05 (3)
90 3746 4459 0.10 0.08 -0.02 (20)
75 1417 1318 1.30 1.39 0.09 (11)
120 2475 3015 0.40 0.33 -0.07 (20)
75 1436 1654 1.90 1.65 -0.25 (14)
75 1207 1390 1.87 1.62 -0.25 (13)
90 2433 2069 1.58 1.86 0.28 (18)
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Figure 1 Relationship between unadustedepirubicin clearce and body
surfacearea(n= 32)
simulating the exposure to epirubicin (AUC) that each patient in
this study would have received had a standard dose strategy been
employed.
Only at the 75. 90 and 120 mg m-'dose levels were sufficient
patients (>6) treated to assess theimpact ofsurface areaadjustment
on AUC. For these dose levels the mean total dose of epirubicin
administered was calculated. As there was a linear relationship
I
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Figure 2 Relationship between actualand predicted neutrophil nadir count
(n= 11)
between dose and AUC. the AUC each patient would have experi-
enced given that mean total dose was calculated as:
observed AUC x mean dose (mg) Predicted AUC =
Actual dose (mg)
Table 3 shows the observed AUC (resulting from the mg m-2 dose
ofepirubicin administered),and the predicted AUC (had a standard
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dose ofepirubicin been given). The variability in AUC. expressed
as CV%, was the same for the observed AUC and the predicted
AUC. The accuracy ofthe predicted AUC was confirmedby MPE
values of 1.1 (at 120mg m-2). 1.1 (at 90mg M-2) and 1.2 (at
75 mg m-'). Precision in the predicted AUC was demonstrated by
the MAPE values of8.6(at 120mgm-2), 8.0(at 90mg m-2) and 9.8
(at 75 mg m-2).
Impact of surface area dose adjustment on
pharmacoynamics(myelosup on)
Nadirblood counts were available for 11 ofthe 32patients and are
shown below. There was a strong correlation between epirubicin
AUC and the observedneutrophil nadir(r = 0.85, P <0.001). This
was reflected in the significantly higher AUC of the five patients
with grade 3/4 neutropeniacompared with the six with less severe
myelosupression (4363 and 1611 ng mll h respectively, P = 0.01
Mann-Whitney test).
The relative importance of treatment (epirubicin dose),pharma-
cokinetic (AUC) and patient characteristics (age, height, body
weight, % IBW and pretreatment blood counts) in determining
leucopenia and neutropenia was investigated using multiple
regression analysis. Epirubicin AUC had the strongestrelationship
with both the absolute neutrophil nadir (r2 = 0.72) and total WBC
nadir(r2 =0.63). Thisrelationship was stronger than that ofepiru-
bicin dose withneutrophil nadir or WBC nadir(r2 = 0.51 and 0.47
respectively). Similarly, epirubicin AUC was the only parameter
strongly associated with the surviving fraction ofboth neutrophils
and total WBC (r2 = 0.62 and 0.57 respectively).
The potential clinical impact ofadministering standard doses of
epirubicin was explored by estimating the neutropenia that each
patient would have experienced had this strategy been employed.
The predicted AUC for administration of a standard dose ofepiru-
bicin had been calculated above for the 11 patients for whom nadir
counts were available. All received single agent epirubicin 75-
120 mg m-'. Given the linear relationship between AUC and
neutrophilnadir described above, the nadirthat each patient would
have experienced had they been exposed to the predicted AUC
was calculated as:
Predicted observed neutrophil nadir x observed AUC
neutrophil =Predicted AUC
nadir
Table 4 shows the observed neutrophil nadir (resulting from the
mg m-2 dose of epirubicin administered) and the predicted AUC
(that would be expected had an unadjusted dose ofepirubicinbeen
given). The median observed and predicted nadirs were 1.07 and
0.96 x 1091-'respectively. There was also nodifference in the vari-
ability of the observed and predicted nadirs, both having CVs of
71%. The relationship between the observed and predicted
neutrophil nadirs is shown in Figure 2. The accuracy and precision
of the predicted neutrophil count was confirmed by an MPE and
MAPE of4.5% and 11.6 respectively.
DISCUSSION
The most important finding in this paper is that there is no rela-
tionship between totalplasma clearance ofepirubicin and any clin-
ical or biochemical parameter orphysical characteristic, including
body surface area. Theimplication ofthese data is thatabandoning
surface area normalization of epirubicin would not increase the
variability in AUC, nor would it significantly affect neutropenia. a
measure ofepirubicin pharmacodynamics.
These data support the smaller study by Cosolo et al (1994) who
also reported no relationship between epirubicin clearance and
surface area, although there did appearto be acorrelation with lean
body mass. Taken with work by Grochow et al (1990) these phar-
macokinetic data cast serious doubts on the aptness ofnormalizing
doses according to surface area. It is, however, pharmacodynamic
parameters (response or toxicity) that are important in clinical
practice. In the current study neutropenia was correlated with
epirubicin AUC. Indeed, in a multivariate analysis AUC predicted
the neutrophil nadir more strongly than dose of epirubicin or any
physical or physiological variable. Other studies have also shown
that myelosuppression is influenced by the AUC of epirubicin
(Jakobsen et al, 1991), doxorubicin (Ackland et al. 1989) and
iododoxorubicin (Robert et al, 1992; Twelves et al, 1994).
Therefore, as surface area normalization does not affect epirubicin
AUC,it may alsodo little to reduce interpatientvariability in treat-
ment outcome. We investigated this further by studying the effect
of abandoning surface area normalization on neutropenia. This
analysis suggested that abandoning surface area dose normaliza-
tion would not significantly alter the pattern ofmyelosuppression.
These findings have potentially important implications.
although they should be viewed with some caution as the patients
had a relatively narrow range of surface areas. albeit a range that
includes most patients who receive chemotherapy. The first ques-
tion is whetherthere are good reasons to continue normalization of
epirubicin dose for surface area. Dosing considerations vary in
different clinical settings. In situations in whichepirubicin is given
with curative intent, and dose intensity may be perceived as of
paramount importance, clinicians may be especially reluctant to
abandon surface area normalization. Epirubicin is, however, often
given as palliative treatment when modest differences in dose
intensity are unlikely to be significant. Indeed, there are important
potential advantages to abandoning routine use of surface area
adjustment. Firstly. it would reduce drug wastage and may
increase the safety of prescription. Secondly. in routine clinical
practice surface area normalization creates the illusion that accu-
rate dose modifications are made for each individual patient. This
may deter clinicians from making dose modifications according to
other factors such as the tolerability ofearlier cycles oftreatment.
The majorpossible drawback offorsaking surface area adjustment
is that it may lead to overtreatment of 'small' patients and under-
treatment of 'large' patients. There is little evidence to support
this. Indeed, very large patients are often treated at doses modified
for their ideal (rather than actual body) weight or have their
surface area 'rounded down' to 2.0 min.
There are potentially more important implications of ending
routine surface area normalization in the area of new drug devel-
opment It is certainly appropriate to use surface area normaliza-
tion to calculate the starting dose for phase I studies as this is
extrapolated from animal toxicology data. However,for individual
patients it may be more rational not to adjust dose according to
surface area. The primary aimsofphase I studies include identifi-
cation ofthe maximum tolerated dose and proposed phase IIdose
for a new agent. By assuming that this should be adjusted for
surface area we may not fully accomplish that aim. Similarly,
phase I trials also aim to determine the causes ofpharmacokinetic
and pharmacodynamic variability. The importance of physical
British JournalofCarner(1998) 78(5), 662-666 0CancerResearchCampaign 1996666 NA Dobbs and CJ Twelves
characteristics may best be assessed by first using unadjusted
drug doses. as for biochemical and haematological parameters.
provided the patients surface area fell within normal limits'. As
data on pharmacokinetics and toxicity are collected the determi-
nants of variability should be studied svstematicallv. and. when
appropriate. incorporated at higher dose levels in the phase I study.
These data could then be confirmed by population pharmaco-
kinetic studies in phase II trials.
The current study has shown that there is wide variability in
epirubicin pharmacokinetics despite normalization of doses for
surface area. Administration of fixed doses of epirubicin would
not increase the variability in epirubicin AUC. Likewise. from a
clinical perspective. it appears that fixed dosing would not signifi-
cantlv alter the pattern of myelosuppression. There is a need to
evaluate systematically the sources of variability in pharmaco-
kinetics and pharmacodynamics in order to develop rational dose
recommendations. In some cases this will involve surface area
normalization but in others alternate dose strategies may be identi-
fied. These considerations apply to drugs in clinical use but are
maybe even more relevant for agents under development.
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